Department of Pathology and Pathophysiology, School of Basic Medicine, Anhui Medical College, Hefei, China.
J Cell Mol Med. 2024 Aug;28(16):e70031. doi: 10.1111/jcmm.70031.
Hepatocellular carcinoma (HCC) is a common and lethal liver cancer characterized by complex aetiology and limited treatment options. FAM210B, implicated in various cancers, is noteworthy for its potential role in the progression and treatment response of HCC. Yet, its expression patterns, functional impacts and correlations with patient outcomes and resistance to therapy are not well understood. We employed a comprehensive methodology to explore the role of FAM210B in HCC, analysing its expression across cancers, subcellular localization and impacts on cell proliferation, invasion, migration, biological enrichment and the immune microenvironment. Additionally, we investigated its expression in single cells, drug sensitivity and relationships with genomic instability, immunotherapy efficacy and key immune checkpoints. While FAM210B expression varied across cancers, there was no notable difference between HCC and normal tissues. Elevated levels of FAM210B were associated with improved survival outcomes. Subcellular analysis located FAM210B in the plasma membrane and cytosol. FAM210B was generally downregulated in HCC, and its suppression significantly enhanced cell proliferation, invasion and migration. Biological enrichment analysis linked FAM210B to metabolic and immune response pathways. Moreover, its expression modified the immune microenvironment of HCC, affecting drug responsiveness and immunotherapy outcomes. High expression levels of FAM202B correlated with increased resistance to sunitinib and enhanced responsiveness to immunotherapy, as evidenced by associations with tumour mutation burden, PDCD1, CTLA4 and TIDE scores. FAM210B exerts a complex influence on HCC, affecting tumour cell behaviour, metabolic pathways, the immune microenvironment and responses to therapy.
肝细胞癌（HCC）是一种常见且致命的肝癌，其病因复杂，治疗选择有限。FAM210B 与多种癌症有关，其在 HCC 的进展和治疗反应中的潜在作用值得关注。然而，其表达模式、功能影响以及与患者预后和对治疗的耐药性的相关性尚不清楚。我们采用了一种全面的方法来研究 FAM210B 在 HCC 中的作用，分析了其在癌症中的表达、亚细胞定位以及对细胞增殖、侵袭、迁移、生物学富集和免疫微环境的影响。此外，我们还研究了其在单细胞中的表达、药物敏感性以及与基因组不稳定性、免疫治疗疗效和关键免疫检查点的关系。虽然 FAM210B 的表达在各种癌症中有所不同，但在 HCC 与正常组织之间没有明显差异。FAM210B 水平升高与生存结局改善相关。亚细胞分析将 FAM210B 定位在质膜和细胞质中。FAM210B 在 HCC 中通常下调，其抑制显著增强了细胞增殖、侵袭和迁移。生物学富集分析将 FAM210B 与代谢和免疫反应途径联系起来。此外，其表达改变了 HCC 的免疫微环境，影响了药物反应性和免疫治疗结果。FAM202B 的高表达水平与对舒尼替尼的耐药性增加和对免疫治疗的反应性增强相关，这与肿瘤突变负担、PDCD1、CTLA4 和 TIDE 评分有关。FAM210B 对 HCC 有复杂的影响，影响肿瘤细胞行为、代谢途径、免疫微环境以及对治疗的反应。
